ETF · VanEck
CURG VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD
ISIN IE000B9PQW54London Stock Exchange: CURGVanEck ETP AG
- Healthcare
- ETF
- ISA
- SIPP
- Accumulating
Latest close
LSE£20.36
on
- Ongoing charge
- 0.35% a year
- Fund size
- £18.7m
As of , at least 15 min delayed
At a glance
As of 13/11/2026, CURG (VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD, ISIN IE000B9PQW54) closed at £20.36 on the London Stock Exchange. Its ongoing charge is 0.35% a year (about £35 on £10,000). Over the three years to 13/11/2026 its price changed by +51.7%, or +37.0% after UK CPIH inflation.
Past returns
- 1 year to 13/11/2026
- +20.8%
- +16.5% after inflation (UK CPIH)
- 3 years to 13/11/2026
- +51.7%
- +37.0% after inflation (UK CPIH)
Returns: as reported (delayed data) and worked out from recorded daily closes. Inflation: UK CPIH, latest month published.
How we work it out:ReturnsReturns after inflationTotal returnReal returnCPIH
Calendar-year and 12-month returns
Calendar-year returns of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD in pounds (price, with income reinvested in the fund): 2023 −8.5%, 2024 −2.4%, 2025 +7.3%; 2026 to 13/11/2026 +22.7%. Returns of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +32.4%; to 30/09/2025: +9.1%; to 30/09/2024: −1.2%; to 30/09/2023: −15.0%.
| Year | Return | After inflation | Return shown as a bar |
|---|---|---|---|
| to | +22.7% | +18.8% | |
| to | +7.3% | +3.6% | |
| to | −2.4% | −5.7% | |
| −8.5% | −12.2% |
| 12 months to | Return | After inflation |
|---|---|---|
| from | +32.4% | +27.7% |
| from | +9.1% | +4.8% |
| from | −1.2% | −3.7% |
| from | −15.0% | −20.1% |
As of , inflation: UK CPIH
How we work it out:Calendar-year returnsWhat a calendar-year return isAccumulating and distributing
Risk: volatility and largest fall
Volatility (annualised)
22.4%over 3 years
| 1 year | 29.1% |
|---|---|
| 3 years | 22.4% |
Annualised from weekly returns. Higher means bumpier.
- Largest fall since September 2022
- −33.0%
- From to
- Lowest 12-month return
- −26.3%
- 12 months to
- Highest 12-month return
- +31.7%
- 12 months to
- Below its highest weekly close since September 2022
- 6.2%
- High of , latest
In words: Volatility of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD in pounds, annualised from weekly returns to 13/11/2026: 29.1% over 1 year, 22.4% over 3 years. Largest fall in the price of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD since September 2022, in pounds: −33.0% from 09/09/2022 to 11/04/2025. The lowest 12-month return of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD in pounds (price, with income reinvested in the fund) since September 2022 was −26.3% (12 months to 10/11/2023); the highest was +31.7% (12 months to 09/10/2026). On 13/11/2026 the price of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD was 6.2% below its highest weekly close since September 2022 (30/10/2026), in pounds.
As of , price, with income reinvested in the fund
How we work it out:Risk figuresFallsVolatilityLargest fall
Charges compared with similar funds
- Ongoing charge
- 0.35%
- a year
- On £10,000
- £35
- a year, roughly
- Over five years
- £174
- of £10,000, before growth
- 14 charge less
- 3 the same
- 11 charge more
Ongoing charge of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD 0.35% a year. Compared on 14/11/2026, 11 of the 28 other healthcare funds charge more, 3 the same and 14 less (share classes counted once).
As of
A lower charge is not a promise of a higher return: what the fund holds matters more.
As of
Read more:Ongoing charge (OCF)OCF and TERFee dragHow charges add up
In plain English
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD is an exchange-traded fund (ETF) from VanEck, launched in 2022.
It tracks the MVIS Global Future Healthcare ESG Index - Benchmark TR Net.
You buy and sell it through a share-dealing account or platform during stock-market hours, like a share.
Its ongoing charge is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund's value rather than billed to you.
Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
Healthcare: Pharmaceutical, biotech and medical-equipment companies.
Terms:ETFIndex fundUCITSAccumulating or incomeShare classISIN
Key facts
- Ticker
- CURG
- ISIN
- IE000B9PQW54
- Also listed as
- CURE (London Stock Exchange, US dollars)
- Provider
- VanEck
- Structure
- ETF
- An exchange-traded fund: bought and sold on the stock exchange through the day, like a share.
- Income
- Accumulating
- Income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
- Ongoing charge
- 0.35% a year · about £35 on £10,000
- Fund size
- £18.7m
- Launched
- Domicile
- Ireland
- UK reporting fund status
- Yes — on HMRC’s list of reporting funds (list of )
- Reporting fund since . What reporting fund status means
- Can usually be held in
- ISA and SIPP
- Check with your platform: each decides which funds it offers.
- Currency hedged
- No
- Price currency
- Pounds (GBP)
- Category
- Healthcare
Price chart
Over the last year, the closing price went from £16.93 on 14/11/2025 to £20.36 on 13/11/2026 (+20.3%). The lowest close shown was £14.55 on 15/05/2026 and the highest £21.72 on 30/10/2026.
One close a week. Before 14/08/2026 the closes are from the weekly price history for this listing; from then on, the closing prices we have recorded.
As of , at least 15 min delayed
Five years of prices, and after inflation
213 weekly closes, from 09/09/2022 to 13/11/2026. The same history in November 2026 pounds, adjusted with CPIH inflation.
Create a free account to see the 5-year price chart and the after-inflation chart
Sign-up takes an email address. There is no card to enter and nothing to pay.
How we work it out:Prices and returnsNAV and price
What it holds
- Holdings
- 50
- on record
- Ten largest
- 61.6%
- of the whole fund
- Effective number of holdings
- 20
- As concentrated as this many equal-sized holdings (how it is worked out)
- Largest holding
- 11.2%
- Moderna
Top 10 holdings
| Rank# | Holding | Weight as a percentage of the fund |
|---|---|---|
| 1 | ModernaMRNAHealth CareUnited States | 11.16% |
| 2 | Regeneron PharmaceuticalsREGNHealth CareUnited States | 9.16% |
| 3 | Vertex PharmaceuticalsVRTXHealth CareUnited States | 8.00% |
| 4 | Veeva SystemsVEEVHealth CareUnited States | 7.27% |
| 5 | NateraNTRAHealth CareUnited States | 5.61% |
| 6 | DexComDXCMHealth CareUnited States | 5.29% |
| 7 | IlluminaILMNHealth CareUnited States | 4.89% |
| 8 | Guardant HealthGHHealth CareUnited States | 4.06% |
| 9 | BioNTechBNTXHealth CareGermany | 3.39% |
| 10 | Alnylam PharmaceuticalsALNYHealth CareUnited States | 2.79% |
As of , holdings as published
Where it invests
The portfolio by sector, country and type of asset, as a share of the whole fund. Bonds, cash and positions without a classification are shown as they come, not guessed.
By sector
- Health Care97.1%
- Consumer Staples2.9%
By country
- United States85.6%
- China4.1%
- Germany3.4%
- Australia2.3%
- Japan1.3%
- Sweden1.2%
- Switzerland1.0%
- United Kingdom0.5%
- Other countries0.5%
See the full portfolio
Every holding with search and filters, the whole breakdown by sector, country and type of asset, a map of the 50 largest and what changed since .
More of the portfolio
The fund publishes 50 holdings; the ten largest make up 61.6% of it. The fund's portfolio is also split by currency.
Create a free account to see the full holdings list and the currency, maturity and credit-quality breakdowns
Sign-up takes an email address. There is no card to enter and nothing to pay.
Holdings:Compare what it holds with another fundHoldings overlapHow overlap is measured
Funds tracking the same index
2 funds track MVIS Global Future Healthcare ESG Index - Benchmark TR Net, this one included and share classes counted once; their ongoing charges range from 0.35% to 0.45% a year (13/11/2026).
| Fund | Charge | 1 year |
|---|---|---|
| VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USDThis fundAccumulating · 0.35% a year | 0.35% | +20.8% |
| VanEck Sustainable Future of Food UCITS ETF Accum A USDAccumulating · 0.45% a year | 0.45% | −2.6% |
As of
MVIS Global Future Healthcare ESG funds compared: charges, sizes and share classes
Read more:Index fundsTracking differenceHow funds are compared
Other versions of this fund
Risk and return in depth
Sharpe, Sortino and Calmar ratios
Sharpe, Sortino and Calmar ratios over 1 and 3 years, from weekly returns in pounds.
With a free accountRolling returns
The full range of 161 rolling 12-month returns since September 2022, in pounds, with how often they were above zero.
With a free accountLargest falls and recoveries
The 2 largest falls since September 2022, in pounds, with how many weeks each took to reach its low and to recover.
With a free account
Create a free account to see the risk ratios, every rolling return and each large fall and its recovery
Sign-up takes an email address. There is no card to enter and nothing to pay.
Rank among similar funds
Rank by total return over 1 year among up to 11 healthcare funds investing globally, not currency-hedged, highest first.
ProMoves compared with a similar fund
Correlation and beta of weekly returns in pounds against iShares Core MSCI World UCITS ETF, over the three years to 13/11/2026 (147 weeks).
Pro
Pro — currently by invitation
Pro includes the rank among similar funds and moves against a comparable fund
Pro is open by invitation while it is being built. There is nothing to buy. To ask about access, email [email protected].
Questions people ask
What is the ongoing charge of CURG?
The ongoing charge of CURG is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD 0.35% a year. Compared on 14/11/2026, 11 of the 28 other healthcare funds charge more, 3 the same and 14 less (share classes counted once).
What does CURG track?
CURG tracks the MVIS Global Future Healthcare ESG Index - Benchmark TR Net.
Is CURG accumulating or distributing?
CURG is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
What is the ISIN of CURG?
The ISIN of CURG is IE000B9PQW54. An ISIN identifies one exact share class of a fund; CURG is its ticker on the London Stock Exchange. The same share class is also listed as CURE (London Stock Exchange, US dollars).
What does CURG hold?
As of 13/11/2026, CURG holds 50 positions, according to its published holdings. The largest is Moderna at 11.16% of the fund; the ten largest make up 61.6%. Its ten largest holdings are Moderna (11.16%), Regeneron Pharmaceuticals (9.16%), Vertex Pharmaceuticals (8.00%), Veeva Systems (7.27%), Natera (5.61%), DexCom (5.29%), Illumina (4.89%), Guardant Health (4.06%), BioNTech (3.39%) and Alnylam Pharmaceuticals (2.79%).
What were CURG’s returns in each of the last five years?
Calendar-year returns of CURG in pounds (price, with income reinvested in the fund): 2023 −8.5%, 2024 −2.4%, 2025 +7.3%; 2026 to 13/11/2026 +22.7%. Past performance is not a guide to future returns.
How has CURG done after inflation?
Over the three years to 13/11/2026 CURG’s price changed by +51.7%, or +37.0% after UK CPIH inflation. Past performance is not a guide to future returns.
Similar funds
- XWHSXtrackers MSCI World Health Care UCITS ETF0.25% a year · £3.4bn
- IHCUiShares S&P 500 Health Care Sector UCITS ETF0.15% a year · £2.7bn
- DRDRiShares Healthcare Innovation UCITS ETF0.40% a year · £1.3bn
- XSHCXtrackers MSCI USA Health Care UCITS ETF0.12% a year · £1.2bn
- BTEKiShares NASDAQ US Biotechnology UCITS ETF0.35% a year · £1.0bn
- CH5Amundi STOXX Europe 600 Healthcare UCITS ETF -Acc- Capitalisation0.30% a year · £833m
- ESIHiShares MSCIEurope Health Care Sector UCITS ETF AccumEUR0.18% a year · £798m
- 0DW6Amundi MSCI World Health Care UCITS ETF EUR ACC0.30% a year · £792m
Fund documents and methods
Methodology:ReturnsCategoriesAll methods
A machine-readable copy of this page: Markdown.